BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Figure out How to Explore the Infotainment Framework in the Slam 1500. - 2Everyday Seasonal Positions That Compensate Fairly in the US
- 3Plane Passenger Allegedly Includes ‘Bomb Threat’ in Hotspot Network Name, Forces Flight to Make Emergency Landing
- 4Paratroopers kill terrorist who threw rocks at Israeli citizens, soldiers near Ofra in West Bank
- 5A top Marine shares his secrets to keeping fit at 50
- The Electric Bicycle Americans Can Confide in 2024
- From candy cane fishing to ornament switcharoo, here are some of the best games you can play with your loved ones this holiday season
- Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world
- First Alert: Light snow through this evening
- Sustaining Public activity and Connections: Key Methodologies
- 6 Web-based Course Stages for Successful Learning and Educating
- UK can legally stop shadow fleet tankers, ministers believe
- Thermo Fisher wins contracts as pharma shifts production to US, CEO says
- Dear Santa: I want Botox. Why cosmetic procedures are topping holiday wish lists.
